142 related articles for article (PubMed ID: 18252132)
1. Failure of isoniazid chemoprophylaxis during infliximab therapy.
Fernández-Guerrero ML; Esteban J; Acebes C; Górgolas M
Emerg Infect Dis; 2007 Sep; 13(9):1428-9. PubMed ID: 18252132
[No Abstract] [Full Text] [Related]
2. Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease.
Malkin J; Shrimpton A; Wiselka M; Barer MR; Duddridge M; Perera N
J Med Microbiol; 2009 Mar; 58(Pt 3):371-373. PubMed ID: 19208889
[TBL] [Abstract][Full Text] [Related]
3. Severe sporotrichoid fish tank granuloma following infliximab therapy.
Rallis E; Koumantaki-Mathioudaki E; Frangoulis E; Chatziolou E; Katsambas A
Am J Clin Dermatol; 2007; 8(6):385-8. PubMed ID: 18039022
[TBL] [Abstract][Full Text] [Related]
4. [Pain, swelling, and progressive weakness of the left knee over 6 years].
Pelfort X; Horcajada JP; Puig L; Salvadó M
Enferm Infecc Microbiol Clin; 2008 Nov; 26(9):595-6. PubMed ID: 19100182
[No Abstract] [Full Text] [Related]
5. Rapid improvement of Mycobacterium kansasii pneumonia after rifabutin, isoniazid, and ethambutol: A case report.
Kuo HI; Huang ST; Wu YH
Kaohsiung J Med Sci; 2022 Nov; 38(11):1137-1138. PubMed ID: 36254860
[No Abstract] [Full Text] [Related]
6. [Swelling of right knee in an immunologically compromised patient].
Cajigas-Pezo D; Lorenzo-Hernandez A; Vives-Rivero GR; Rentero-Martínez Z
Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):481-2. PubMed ID: 22521279
[No Abstract] [Full Text] [Related]
7. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
8. [Fever and thin-walled cavitary lung lesions].
Ramos A; Daza R; Alvarez-Espejo T; Guzmán MF
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
[No Abstract] [Full Text] [Related]
9. [Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid].
Ikeue T; Nakagawa A; Furuta K; Morita K; Sugita T; Nishiyama H
Kekkaku; 2011 Nov; 86(11):879-82. PubMed ID: 22250467
[TBL] [Abstract][Full Text] [Related]
10. Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction.
Molton JS; Huggan PJ; Archuleta S
Med J Aust; 2015 Feb; 202(3):156-7. PubMed ID: 25669480
[No Abstract] [Full Text] [Related]
11. Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
Cosson MA; Bertrand JB; Martin C; Veziris N; Picard C; Goulvestre C; Coignard S; Benoit JP; Silvera S; Moro MR; Poyart C; Morand PC
J Med Microbiol; 2012 Nov; 61(Pt 11):1617-1620. PubMed ID: 22859583
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium kansasii cutaneous infection in a patient with sarcoidosis treated with anti-TNF agents.
Spiliopoulou I; Foka A; Bounas A; Marangos MN
Acta Clin Belg; 2014 Jun; 69(3):229-31. PubMed ID: 24773076
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with infliximab despite positive tuberculosis ELISpot results in a patient with pityriasis rubra pilaris taking prophylactic isoniazid.
Zirbs M; Kigitsidou E; Seifert F; Ring J; Brockow K
Clin Exp Dermatol; 2011 Oct; 36(7):808-9. PubMed ID: 21507042
[No Abstract] [Full Text] [Related]
14. Disseminated Mycobacterium kansasii infection associated with skin lesions: a case report and comprehensive review of the literature.
Han SH; Kim KM; Chin BS; Choi SH; Lee HS; Kim MS; Jeong SJ; Choi HK; Kim CO; Choi JY; Song YG; Kim JM
J Korean Med Sci; 2010 Feb; 25(2):304-8. PubMed ID: 20119588
[TBL] [Abstract][Full Text] [Related]
15. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Hradilek P; Zeman D; Tudik I; Zapletalova O; Ulmann V
Mult Scler; 2014 Apr; 20(5):639-40. PubMed ID: 23959714
[No Abstract] [Full Text] [Related]
16. Mycobacterium kansasii.
Johnston JC; Chiang L; Elwood K
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28185617
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient.
Tabatabaei N; Stout J; Goldschmidt-Clermont P; Murdoch D
Infection; 2007 Jun; 35(4):291-4. PubMed ID: 17646914
[No Abstract] [Full Text] [Related]
18. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
19. Atypical mycobacterial infection in a patient with hairy cell leukemia.
Trizna Z; Tschen J; Natelson EA
Cutis; 2001 Mar; 67(3):241-2. PubMed ID: 11270299
[TBL] [Abstract][Full Text] [Related]
20. Delayed response to anti-tuberculosis treatment in a patient on infliximab.
Vlachaki E; Psathakis K; Tsintiris K; Iliopoulos A
Respir Med; 2005 May; 99(5):648-52. PubMed ID: 15823465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
